AYTU BIOSCIENCE, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by AYTU BIOSCIENCE, INC. on March 17, 2017, covering events that occurred on March 13, 2017. The company is incorporated in Delaware and operates from Englewood, Colorado.
Key Financial Metrics and Events
The filing details two primary financial and operational events:
- Asset Sale: In the third fiscal quarter of 2017, the company sold all shares of Acerus Pharmaceutics Corporation acquired in April 2016. The gross proceeds from this sale were approximately $1.1 million. The original acquisition cost was approximately $2.0 million, resulting in a realized loss on the investment.
- Executive Compensation: Upon the termination of Jonathan H. McGrael (Vice President of Commercial Operations), the company agreed to pay six months of salary, relocation expenses, and accelerate the vesting of 40,000 unvested options and 140,000 restricted shares.
The filing does not provide consolidated revenue, net income, operating cash flow, debt levels, or liquidity ratios for the reporting period.
Material Changes
The material change reported is the divestiture of the Acerus Pharmaceutics Corporation stake, which was a condition of the company's licensing of Natesto. Additionally, the departure of a senior executive represents a change in management structure.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future strategy, or specific risk factors beyond the disclosed events. The sale of the Acerus shares was executed as a contractual condition for the Natesto license.
Investor Verification Checklist
- Verify the impact of the $0.9 million loss on the Acerus sale on the company's Q3 2017 financial statements.
- Confirm the total cash outflow associated with the accelerated vesting and severance package for the former VP of Commercial Operations.
- Review the status of the Natesto license and its contribution to future revenue streams following the Acerus divestiture.
- Check for any subsequent filings regarding the appointment of a replacement for the departed executive.